ClinicalTrials.gov record
Active, not recruiting Early Phase 1 Interventional

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

ClinicalTrials.gov ID: NCT06011772

Public ClinicalTrials.gov record NCT06011772. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Study identification

NCT ID
NCT06011772
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Early Phase 1
Lead sponsor
Roswell Park Cancer Institute
Other
Enrollment
2 participants

Conditions and interventions

Interventions

  • Bevacizumab Biological
  • Biospecimen collection Procedure
  • Cetuximab Biological
  • Computed Tomography Procedure
  • Fluorouracil Drug
  • Irinotecan Drug
  • Leucovorin Drug
  • Metastasectomy Procedure
  • Oxaliplatin Drug
  • Panitumumbab Biological
  • Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Biological

Biological · Procedure · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 17, 2023
Primary completion
Feb 4, 2026
Completion
Dec 3, 2026
Last update posted
Mar 10, 2026

2023 – 2026

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Roswell Park Comprehensive Cancer Center Buffalo New York 14263

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06011772, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 10, 2026 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06011772 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →